These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32869110)

  • 1. A Multifaceted Perspective of Pharmaceutical Innovation: A Consideration of the Regulatory Role.
    Robberson M; Breder CD
    Ther Innov Regul Sci; 2021 Mar; 55(2):262-269. PubMed ID: 32869110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
    Lanthier M; Miller KL; Nardinelli C; Woodcock J
    Health Aff (Millwood); 2013 Aug; 32(8):1433-9. PubMed ID: 23918488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal study of the impact of three major regulations on the Korean pharmaceutical industry in the last 30 years.
    Um SI; Sohn UD; Jung SY; You SH; Kim C; Lee S; Lee H
    Health Res Policy Syst; 2022 Jan; 20(1):4. PubMed ID: 34991612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers for Pharmaceutical Innovation With Focus in Cancer Drugs, the Case of Mexico.
    Duenas-Gonzalez A; Gonzalez-Fierro A
    Ther Innov Regul Sci; 2020 Mar; 54(2):342-352. PubMed ID: 32072574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the evolution of the pharmaceutical regulatory environment.
    Shafiei N; Ford JL; Morecroft CW; Lisboa PJ; Taylor MJ
    PDA J Pharm Sci Technol; 2013; 67(4):297-306. PubMed ID: 23872441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Keynote review: Is declining innovation in the pharmaceutical industry a myth?
    Schmid EF; Smith DA
    Drug Discov Today; 2005 Aug; 10(15):1031-9. PubMed ID: 16055019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease burden metrics and the innovations of leading pharmaceutical companies: a global and regional comparative study.
    Jung YL; Hwang J; Yoo HS
    Global Health; 2020 Sep; 16(1):80. PubMed ID: 32912258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of biotechnology products in the global pharmaceutical market: the case of the European community and the United States.
    Hakim Z; Kucukarslan S
    Clin Ther; 1993; 15(2):442-58; discussion 432. PubMed ID: 8519050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solving the Global Continual Improvement and Innovation Challenge: How an Effective Pharmaceutical Quality System Can Transform Post-Approval Change Management.
    Vinther A; Ramnarine E
    PDA J Pharm Sci Technol; 2019; 73(5):517-521. PubMed ID: 31420505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
    Pekarsky B
    Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Historical sketch of modern pharmaceutical science and technology (Part 4). Post World War II 50 years].
    Yamakawa K
    Yakushigaku Zasshi; 1995; 30(2):75-90. PubMed ID: 11613536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovation in Chemistry, Manufacturing, and Controls-A Regulatory Perspective From Industry.
    Cauchon NS; Oghamian S; Hassanpour S; Abernathy M
    J Pharm Sci; 2019 Jul; 108(7):2207-2237. PubMed ID: 30794794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On strategic choices faced by large pharmaceutical laboratories and their effect on innovation risk under fuzzy conditions.
    Puente J; Gascon F; Ponte B; de la Fuente D
    Artif Intell Med; 2019 Sep; 100():101703. PubMed ID: 31607342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the research-based pharmaceutical industry in medical progress in the United States.
    Kaitin KI; Bryant NR; Lasagna L
    J Clin Pharmacol; 1993 May; 33(5):412-7. PubMed ID: 8331197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical innovation in the United States. Factors affecting future performance.
    Pollard MR
    Int J Technol Assess Health Care; 1993; 9(2):167-73. PubMed ID: 8458697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovation in the pharmaceutical industry: New estimates of R&D costs.
    DiMasi JA; Grabowski HG; Hansen RW
    J Health Econ; 2016 May; 47():20-33. PubMed ID: 26928437
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.